Header cover image

Commercial Services Healthcare Sector

Results

2304

0 new

All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.

2304 companies

Northwest Biotherapeutics

Market Cap: US$399.7m

A biotechnology company, focuses on developing personalized immune therapies for cancer.

NWBO

US$0.28

7D

-4.6%

1Y

-37.1%

Faron Pharmaceuticals Oy

Market Cap: UK£292.9m

Operates as a clinical stage drug discovery and development company.

FARN

UK£2.35

7D

9.3%

1Y

22.1%

Celcuity

Market Cap: US$395.3m

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

CELC

US$10.44

7D

-1.6%

1Y

-33.2%

Rapport Therapeutics

Market Cap: US$394.9m

Operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.

RAPP

US$10.82

7D

8.6%

1Y

n/a

Tourmaline Bio

Market Cap: US$393.5m

Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.

TRML

US$15.32

7D

-7.5%

1Y

13.9%

Humacyte

Market Cap: US$392.5m

Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

HUMA

US$2.53

7D

12.9%

1Y

-64.6%

EyePoint Pharmaceuticals

Market Cap: US$390.9m

Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.

EYPT

US$5.68

7D

-7.3%

1Y

-49.1%

Verve Therapeutics

Market Cap: US$388.7m

A clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States.

VERV

US$4.36

7D

-5.8%

1Y

-17.4%

AngioDynamics

Market Cap: US$383.7m

A medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally.

ANGO

US$9.45

7D

0.5%

1Y

53.2%

Australian Clinical Labs

Market Cap: AU$575.1m

Provides pathology diagnostic services in Australia.

ACL

AU$2.95

7D

-5.4%

1Y

33.5%

Treace Medical Concepts

Market Cap: US$369.9m

A medical technology company, designs, manufactures, and markets medical devices in the United States.

TMCI

US$5.88

7D

-12.5%

1Y

14.0%

Vigil Neuroscience

Market Cap: US$368.2m

A clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States.

VIGL

US$7.89

7D

216.9%

1Y

117.4%

Organogenesis Holdings

Market Cap: US$367.9m

A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.

ORGO

US$2.90

7D

-5.8%

1Y

10.3%

Fortrea Holdings

Market Cap: US$367.6m

A contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

FTRE

US$4.06

7D

-8.6%

1Y

-84.1%

Aura Biosciences

Market Cap: US$365.2m

A clinical-stage biotechnology company, develops precision therapies to treat solid tumors.

AURA

US$5.89

7D

-1.0%

1Y

-16.2%

NIOX Group

Market Cap: UK£266.7m

Engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide.

NIOX

UK£0.64

7D

-5.6%

1Y

-8.6%

Myriad Genetics

Market Cap: US$360.4m

A molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally.

MYGN

US$3.91

7D

-5.3%

1Y

-83.1%

Mereo BioPharma Group

Market Cap: US$356.2m

A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

MREO

US$2.24

7D

0%

1Y

-24.1%

Quantum-Si

Market Cap: US$356.0m

A life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS).

QSI

US$1.94

7D

31.1%

1Y

19.8%

Prothena

Market Cap: US$354.2m

A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.

PRTA

US$6.58

7D

-8.4%

1Y

-67.2%

CytomX Therapeutics

Market Cap: US$351.3m

Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.

CTMX

US$2.23

7D

9.9%

1Y

27.4%

Checkpoint Therapeutics

Market Cap: US$351.0m

A commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.

CKPT

US$4.19

7D

1.0%

1Y

127.7%

Standard BioTools

Market Cap: US$350.0m

Develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

LAB

US$0.92

7D

-14.7%

1Y

-63.7%

Fulcrum Therapeutics

Market Cap: US$347.6m

A clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

FULC

US$6.44

7D

-6.4%

1Y

-10.7%

Emergent BioSolutions

Market Cap: US$347.4m

A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.

EBS

US$6.40

7D

-3.6%

1Y

34.5%

Clinuvel Pharmaceuticals

Market Cap: AU$532.6m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

CUV

AU$10.65

7D

-0.6%

1Y

-31.6%

Erasca

Market Cap: US$345.6m

A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

ERAS

US$1.22

7D

-5.1%

1Y

-53.6%

Olema Pharmaceuticals

Market Cap: US$344.8m

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

OLMA

US$5.04

7D

7.0%

1Y

-44.4%

TruBridge

Market Cap: US$344.6m

Provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally.

TBRG

US$23.73

7D

-5.2%

1Y

136.4%

Absci

Market Cap: US$339.3m

Operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.

ABSI

US$2.66

7D

-7.6%

1Y

-36.8%

Rigel Pharmaceuticals

Market Cap: US$338.7m

A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.

RIGL

US$18.95

7D

-4.5%

1Y

108.8%

Anbio Biotechnology

Market Cap: US$338.0m

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.

NNNN

US$7.70

7D

2.1%

1Y

n/a

Benitec Biopharma

Market Cap: US$337.7m

A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.

BNTC

US$13.19

7D

-3.0%

1Y

46.2%

ClearPoint Neuro

Market Cap: US$336.1m

Operates as a medical device company primarily in the United States.

CLPT

US$11.89

7D

-9.8%

1Y

102.6%

aTyr Pharma

Market Cap: US$333.8m

A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.

ATYR

US$3.75

7D

14.7%

1Y

108.3%

SNDL

Market Cap: US$331.9m

Engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada.

SNDL

US$1.29

7D

-4.4%

1Y

-41.9%

Page 14 of 64